Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership to Develop First-in-Class Gene Therapy for Cystic Fibrosis
INGELHEIM, Germany–(BUSINESS WIRE)– This new collaboration unites leaders in cystic fibrosis gene therapy, lentiviral development and production, and the treatment of respiratory diseases to develop...